OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC

June 21st 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.

Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC Diagnoses

June 21st 2019

Ana Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.

Dr. McCulloch on Data Supporting the Use of R-BAC in MCL

June 21st 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses data supporting the use of R-BAC (rituximab [Rituxan], cytarabine, and bendamustine) in mantle cell lymphoma (MCL).

Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer

June 21st 2019

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.

Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLC

June 21st 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).

Dr. El-Khoueiry on the Role of Ramucirumab in Advanced HCC

June 20th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses the role of ramucirumab in advanced hepatocellular carcinoma.

Expanding the Use of Immunoscore in Early-Stage CRC

June 20th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer.

Dr. Langer on the Current State of Immunotherapy in Advanced NSCLC

June 20th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the current state of immunotherapy in advanced non–small cell lung cancer.

Dr. Sands on the Rationale to Explore DS-1062 in Advanced NSCLC

June 20th 2019

Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non–small cell lung cancer (NSCLC).

Dr. Gainor on Potential With BLU-667 in RET+ NSCLC

June 20th 2019

Justin F. Gainor, MD, director of targeted immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses clinical activity and tolerability of BLU-667 in patients with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Dr. Rao on Abemaciclib Post-Palbociclib in Metastatic Breast Cancer

June 20th 2019

Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.

Dr. Pecora on Updated MAIA Data in Multiple Myeloma

June 20th 2019

Andrew Pecora, MD, FACP, CPE, president physician enterprise, chief innovation officer, John Theurer Cancer Center, Hackensack Meridian Health, discusses the impact age has on the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (DRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) as part of the MAIA study.

Dr. Barr on Updated RESONATE Data in IGHV-Mutant CLL

June 20th 2019

Paul Barr, MD, medical director, Cancer Center Clinical Trials Office, and assistant professor, School of Medicine and Dentistry, University of Rochester, discusses the 6-year follow-up in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) on ibrutinib (Imbruvica) as part of the RESONATE study.

Dr. Penson on Olaparib Monotherapy Vs Chemo in Ovarian Cancer

June 20th 2019

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Massachusetts General Hospital, compares olaparib (Lynparza) monotherapy with chemotherapy for patients with relapsed germline BRCA-mutated (gBRCAm) platinum-sensitive ovarian cancer.

Dr. Mouw on the Role of Radiation Therapy in Prostate Cancer

June 20th 2019

Kent W. Mouw, MD, PhD, co-director, Bladder Cancer Center, assistant professor, Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of radiation therapy in prostate cancer.

Dr. Pecot on the Frontline Standard of Care in Squamous NSCLC

June 20th 2019

Chad Pecot, MD, assistant professor, Department of Medicine, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, discusses the frontline standard of care in advanced squamous non–small cell lung cancer (NSCLC).

Dr. Lee on Inclusion Criteria of the ARAMIS, SPARTAN, and PROSPER Trials in M0CRPC

June 20th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses inclusion criteria of the phase III ARAMIS, SPARTAN, and PROSPER trials in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Dr. Philip Discusses the Use of Lutathera in NETs

June 19th 2019

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the use of Lutathera in neuroendocrine tumors.

Dr. Lenz on Next Steps With Immunotherapy in mCRC

June 19th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

Dr. Elhassadi Discusses the Outlook of Patients With p53-Mutated MCL

June 19th 2019

Ezzat Elhassadi, MD, consultant hematologist, Haematology Services, University Hospital Waterford, discusses the outlook of patients with p53-mutated mantle cell lymphoma.